The following article was reprinted with permission from Medical Economics magazine, another of Advanstar Medical Economics Healthcare publications. Weiss is senior editor of Medical Economics. For more information on the article, please visit Medical Economics MagazineYour receptionist lets you know that a Dr. Smith is on the phone, and he's checking the references of Jane Miller, a former staffer. You and your employees are thrilled that Jane no longer works for you. She was chronically late, sloppy, rude to patients, and was about to be fired when she quit, ostensibly for family reasons, about a year ago. "What should I tell him? Do you want to talk to him?"
A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
At a Dermatology Times Case-Based Roundtable event, Carolyn Goh, MD, led clinicians through a discussion of severity scoring, patient-reported outcomes, CYP2C9 testing, and long-term monitoring across 3 alopecia areata cases.
Gaurav Singh, MD, MPH, explains how pharmacokinetics, trial design, and real-world tolerability set sonidegib apart from vismodegib in locally advanced basal cell carcinoma and when to start systemic therapy earlier.